为使投资者能够进一步了解公司的生产经营等情况，公司定于 2023 年 5 月 18 日（星期四）15:00－17:00 在全景网举办 2022 年度业绩网上说明会，本次年 度业绩说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动 平台"（http://rs.p5w.net）参与互动交流。 出席本次说明会的人员有：公司董事长高晓东先生、财务总监王军先生、董 事会秘书刘中英先生、独立董事曹德英先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩网上说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 17 日（星期三）17:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的 问题进行回答。 证券代码：300255 证券简称：常山药业 公告编号：2023-22 河北常山生化药业股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 ...

Financial Performance - Net profit for the period was 558,681.84 CNY, a significant decline from 28,851,938.26 CNY in the previous period, indicating a drop of approximately 98.1%[1] - Basic and diluted earnings per share were both 0.0049 CNY, down from 0.0317 CNY in the previous period, a decrease of about 84.5%[4] - Total comprehensive income attributable to the parent company was 3,861,127.43 CNY, compared to 27,986,439.91 CNY in the previous period, a decrease of about 86.1%[4] - Operating profit for the period was 5,752,668.19 CNY, down from 33,283,613.23 CNY, a decrease of approximately 82.7%[1] - The total profit for the period was 5,744,169.24 CNY, significantly lower than 33,232,129.93 CNY in the previous period, indicating a decline of about 82.7%[1] - Net profit attributable to shareholders of the listed company was ¥4,541,481.07, down 84.68% from ¥29,651,405.14 year-on-year[39] - The net profit after deducting non-recurring gains and losses was -¥5,467,837.78, a decline of 120.01% compared to ¥27,324,880.94 in the previous year[39] - Net profit attributable to the parent company decreased by 84.68% year-on-year, mainly due to reduced sales revenue and increased operating costs[58] Revenue and Costs - Total operating costs for the period were 507,965,611.18 CNY, a decrease from 542,640,735.36 CNY in the previous period, representing a reduction of approximately 6.35%[1] - Cash received from sales of goods and services was 516,943,367.04 CNY, down from 567,261,182.52 CNY, a decline of approximately 8.8%[5] - Total operating revenue for the first quarter was ¥501,924,319.12, a decrease of 12.58% compared to ¥574,179,074.10 in the same period last year[39] - The company's operating revenue decreased by 12.58% year-on-year, primarily due to a decline in the price of heparin raw materials and a drop in sales volume of low molecular weight heparin[58] - Sales expenses decreased by 34.42% compared to the same period last year, mainly due to a decrease in sales revenue[45] Cash Flow - The net cash flow from operating activities was -99,744,873.23, an improvement from -158,674,887.67 in the previous period, indicating a 37% reduction in cash outflow[8] - Cash flow from operating activities increased by 37.14% year-on-year, primarily due to a decrease in cash paid for purchasing goods and receiving services[59] - Cash flow from investing activities decreased by 32.88% year-on-year, mainly due to reduced cash payments for the purchase of fixed assets, intangible assets, and other long-term assets[60] - Cash flow from financing activities decreased by 104.61% year-on-year, primarily due to increased cash payments for debt repayment and decreased cash received from borrowings[60] Assets and Liabilities - The total assets decreased to 5,988,652,588.93 from 6,035,803,472.83, reflecting a decline of approximately 0.78%[13] - Current assets totaled 3,768,013,582.66, down from 3,897,553,391.47, indicating a decrease of about 3.32%[13] - Inventory increased slightly to 2,457,407,774.07 from 2,431,477,436.45, showing a growth of approximately 1.06%[13] - The company's long-term assets increased to 2,220,639,006.27 from 2,138,250,081.36, representing a growth of about 3.84%[13] - The short-term borrowings rose to 1,034,922,546.84 from 971,316,007.39, an increase of approximately 6.5%[13] - Total cash inflow from financing activities was 256,504,238.08, down 42% from 439,130,477.50 in the previous period[8] - The total cash outflow from financing activities was 273,066,875.93, significantly higher than 79,967,821.89 in the previous period, resulting in a net cash flow from financing activities of -16,562,637.85[8] Other Financial Metrics - The company reported a net loss from credit impairment of 1,598,914.09 CNY, contrasting with a gain of 1,408,421.45 CNY in the previous period[1] - Other comprehensive income after tax was -680,353.64 CNY, compared to -1,664,965.23 CNY in the previous period, showing an improvement[4] - Accounts receivable financing increased by 55.40% compared to the beginning of the period, mainly due to an increase in AAA-rated bills[30] - Other income increased by 221.52% year-on-year, primarily due to an increase in government subsidies received during the period[33] - Minority interests decreased by 99.02% compared to the beginning of the period, mainly due to the net loss of the controlling subsidiary during the period[32] - Minority interest loss decreased by 398.18% year-on-year, primarily due to a decrease in net profit of the controlling subsidiary[46] - Other current assets increased by 78.14% compared to the beginning of the period, mainly due to an increase in deductible input tax[43] - Accounts receivable decreased by 86.03% compared to the beginning of the period, mainly due to a reduction in non-AAA rated notes[42] - Accounts payable decreased by 72.85% compared to the beginning of the period, primarily due to a reduction in note settlement business[44]

Production Capacity and Product Development - The company is expanding its heparin raw material production capacity by 35 tons to address capacity bottlenecks and enhance net profit margins from heparin raw materials[7]. - The company is actively promoting the bulk export and international registration of non-pig heparin products[8]. - The company has developed advanced biochemical technologies that significantly improve product yield and reduce production cycles, achieving standards higher than industry norms[2]. - The company plans to expand its raw material drug production capacity and actively promote innovative drug research and development[147]. - The company is actively developing non-pig source low molecular weight heparin, with successful HALAL certification for bovine heparin sodium products in Indonesia and Malaysia[155]. - The company is advancing the clinical trials for Abenatide injection, with all subjects enrolled by January 2022, and is progressing with two anti-tumor targeted new drugs in preclinical research[154]. - The company’s research institute focuses on expanding its heparin product line, polysaccharide and peptide products, and developing anti-tumor drugs, with increased investment in R&D planned for the coming years[172]. Financial Performance - The company achieved operating revenue of CNY 2,336.23 million in 2022, a decrease of 21.29% compared to the previous year[129]. - The net profit attributable to shareholders was CNY 17.51 million, representing a decline of 92.50% year-on-year[147]. - Domestic sales accounted for 72.94% of total revenue, while international sales contributed 27.06%, with international sales decreasing by 37.49%[129]. - The gross profit margin for the biopharmaceutical sector was 45.71%, down 13.44% from the previous year[130]. - Revenue from low molecular weight heparin preparations dropped by 27.55% to $1,205,645,412.90, representing 51.61% of total revenue[187]. - Revenue from ordinary heparin raw materials was $596,724,641.10, accounting for 25.54% of total revenue, down 13.78%[187]. - The revenue from ordinary heparin preparations surged by 196.24% to $35,517,662.19, making up 1.52% of total revenue[187]. - Other revenue sources contributed $63,319,199.97, which is 2.71% of total revenue, down 19.86% year-over-year[187]. Corporate Governance and Internal Control - The company maintains a strong commitment to corporate governance, ensuring compliance with relevant laws and regulations[13]. - The company emphasizes talent development and has established a drug research institute to ensure continuous technological innovation[4]. - The company is optimizing its internal control system to mitigate management risks and enhance operational efficiency[10]. - The independent directors provided impartial opinions on the annual profit distribution plan and external guarantees during the reporting period[35]. - The company has maintained a risk-oriented approach in its internal control supervision activities, with no significant issues reported during the period[37]. - The company has not encountered any significant internal control deficiencies in financial reporting during the reporting period[96]. - The company has a complete mechanism for determining the remuneration of directors and senior management based on performance and capability assessments[63]. Environmental Compliance - The company has completed environmental impact assessments for multiple projects, including a series of polysaccharide and protein peptide products[79]. - The company has obtained pollution discharge permits valid until 2026 for its subsidiaries, ensuring compliance with environmental regulations[81]. - The company has implemented a self-monitoring plan for environmental compliance, with all monitoring results meeting the relevant discharge standards[91]. - The wastewater treatment facility processed a total of 42,410.52 tons of wastewater in 2022, with no instances of exceeding discharge standards[87]. - The company’s air pollution control systems, including a chemical deodorization system and a biological deodorization system, operated normally throughout the year, meeting emission standards[111]. - The company has invested approximately CNY 1 million in environmental governance and protection in 2022[119]. - The company has a compensation limit of CNY 3 million for its environmental pollution liability insurance, effective from July 23, 2022, to July 22, 2023[122]. - The company has not reported any penalties or rectification measures during the reporting period[195]. Market Strategy and Sales - The company has established a mature domestic and international marketing network, reducing dependency on any single market[4]. - The company is adjusting its product and customer structure to adapt to market changes, aiming for higher sales revenue[7]. - The company has a complete and independent production and sales system, allowing for autonomous decision-making and contract signing[50]. - The company has continuously improved its internal control system to adapt to changing external environments and internal management requirements[44]. - The company has established a unique competitive advantage in the industry through 20 years of efforts in supply chain management, quality control, international market layout, and independent innovation, ensuring sustainable growth in performance[168]. Shareholder Communication and Dividends - The company proposed a cash dividend of RMB 0.26 per 10 shares (including tax) based on the total share capital after deducting shares in the repurchase account[40]. - The company has not engaged in any investor communication activities during the reporting period[11]. - The company’s profit distribution plan complies with relevant regulations and the company’s articles of association[41]. - The company has a clear and transparent cash dividend policy that aligns with its articles of association and shareholder resolutions[71]. - The company has not proposed a cash dividend distribution plan despite having positive distributable profits for the parent company during the reporting period[72]. Legal Matters - The company has received four lawsuits related to false securities statements in 2022, with one case still under trial, while two claims were dismissed[185]. - There were no related party transactions involving asset or equity acquisitions or sales during the reporting period[196]. - The company did not engage in any related party debt or equity transactions during the reporting period[198]. - There were no significant contracts that contributed to over 10% of the total profit during the reporting period[190].

证券代码：300255 证券简称：常山药业 编号：2014-2 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|----------------------------------------|------------------------------------|----------------------------------------------------|--------| | | √ 特定对象调研 | □ 分析师会议 | | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | | 类别 | □ 新闻发布会 | □ 路演活动 | | | | | □ 现场参观 | | | | | | □ 其他 | （请文字说明其他活动内容） | | | | | 天安财产保险 | 党新星 | 北京大君智萌 | 李红 | | 参与单位名称及 | 北京大君智萌 | 庄伟 | 北京大君智萌 | 杨永清 | | 人员姓名 | 民生证券 | 张金洋 | 深圳裕晋投资 | 许杰 | | ...

Group 1: Company Overview - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is involved in the production of heparin and related products [2] - The company has received registration approval for its new product, Dahuansuan, and has passed the new GMP certification [2] Group 2: Product Development and Market Strategy - The company is actively developing new products, including low molecular weight heparin and Eptifibatide, which are currently awaiting approval [2] - The market for hyaluronic acid appears promising, although current production levels are low [3] Group 3: Supply Chain and Production - The company primarily sources heparin raw materials domestically, with foreign procurement being a minor part [3] - The production workshop for formulations is built according to FDA standards [3] Group 4: Market Coverage and Sales - The low molecular weight heparin injection has approximately 50% coverage in top-tier hospitals, with nearly 2,000 hospitals nationwide using the product [3] - The company’s Dahuansuan raw material is mainly for internal use, while the Jiangsu subsidiary sells its heparin sodium raw materials externally [3]

证券代码：300255 证券简称：常山药业 编号：2014-5 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------|----------------|--------------------|----------------------------------------|----------------------------------------------------| | | √ 特定对象调研 | □ | 分析师会议 | | | 投资者关系活动 | □ 媒体采访 | □ | 业绩说明会 | | | 类别 | □ 新闻发布会 | □ | 路演活动 | | | | □ 现场参观 | | | | | | □ 其他 | | （请文字说明其他活动内容） | | | | 国泰君安 | 王超伟 | 长安基金 | 杨小馨 | | 参与单位名称及 | 千石创富 | 陈仕飞 | 民生证券 | 张金洋 | | 人员姓名 | 兴业证券 | 徐佳熹 | 中航证券 | 胡厚中等 | | 时间 | 2014 年 11 | 月 6 ...

证券代码：300255 证券简称：常山药业 河北常山生化药业股份有限公司 投资者关系活动记录表 编号：2015-1 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 宏道投资 杨洁 | 全尔晖 | | 人员姓名 | 天安财险 党新星 | | | | | | | 时间 | 2015 年 10 月 29 日 | 上午 9:45 | | 地点 | | 河北常山生化药业股份有限公司会议室 | | 上市公司接待人 | 董事会秘书 : 张威 | | | 员姓名 | | | | | | 一、董秘张威介绍了公司三季度经营情况 | | | 二、就公 ...

Group 1: Company Overview and Market Position - The price of heparin sodium raw materials is currently at a relatively low point, with limited downward space [2] - The new low molecular weight heparin raw material workshop has passed German GMP and US FDA certification, which is expected to become a growth point for the company [2] - Sales of low molecular weight heparin calcium injection have been steadily increasing in recent years, and the company's first generic drug, heparin sodium injection, has entered the market and is expected to achieve rapid growth [2] Group 2: Future Plans and Collaborations - The company plans to export heparin preparations to Europe and the US, having already partnered with D.Med Healthcare GmbH&Co.KG in Germany to establish a joint venture for secondary packaging to sell in the European market [2] - The first blood dialysis center is being standardized and has been completed, awaiting expert group acceptance [3] - Clinical trials for Abiraterone have entered Phase I [3] Group 3: Product Development and Regulatory Status - The supplementary application for sildenafil raw materials and formulations was submitted to the National Medical Products Administration in the first half of 2015 and has been accepted; the corresponding production workshop is completed and awaits drug registration approval and GMP certification [3] - The bidding results for low molecular weight heparin calcium injection this year have been good, with stable winning prices; the heparin sodium injection is in the gradual development stage due to its new market entry [3] - The company is currently producing cosmetic-grade and food-grade hyaluronic acid in its pilot workshop, with a new production workshop under construction [3]